Epidemiology, costs and burden of osteoporosis in Mexico

Abstract

Osteoporosis is a serious health condition internationally recognized in developed countries where its impact has been compared with other chronic diseases. Osteoporosis and its related fragility fractures have been reported to have a greater impact on patient quality of life and social costs than breast and prostate cancers.

Epidemiology of orthopedic trauma admissions over year 2017 in the General Hospital H+ in Queretaro Mexico

“…However, qualitative data showed that frequency of patients with the most common type and trauma mechanism of fractures admitted in the Orthopedic Service was consistently increased in female than male genders Tables 1-3; and these groups of results are congruent with previous reports by Johansson H et al [2] and Clark et al [3]. Hence, the more frequent factures in both gender reported in this study Table 2 are similar with that previously reported by Clark et al [3] and the prevalence of fractures obtained in this study (6% in male and 15% in female) was close to the percentages of prevalence (male 9.8% -female 19.2%) reported for vertebral fractures by Clark et al [6,7]. Since the Mexican population is aging and its life expectancy increasing it is expecting the incidence of OP and fragility fractures associated to grow accordingly and to threat the Mexican health system in the near future [1].…”

“…Epidemiological studies have reported the burden of hip and vertebral fractures in Mexico [2,3]. It was published in 2005 that 1 in 12 Mexican women and 1 in 20 Mexican men will undergo a hip fracture after the age of 50.…”

“…The vertebral fractures increase with the age in both genders, and as occurs in many others countries, the vertebral fractures are largely undiagnosed. The incidence of other fragility fractures reported in 2005 by the Mexican Institute of Social Security (IMSS) shown that wrist fractures were the most common reported fracture in persons aged 50 and older, followed by hip, humerus, and pelvis fractures [3].…”

WNT3A gene polymorphisms are associated with bone mineral density variation in postmenopausal mestizo women of an urban Mexican population: findings of a pathway-based high-density single nucleotide screening

“…In the Mexican population, OP is a serious public health problem causing up to 30,000 osteoporotic fractures of the femur or hip every year, with an annual expenditure of about 97 million dollars in health services in 2006. Increased life expectancy in the Mexican population has contributed to a significant increase in the incidence and prevalence of this entity, and it has been estimated that 16 % of women aged above 50 years (1.3 million) are affected with this disease (Clark et al 2010). Both genetic and environmental factors are known to influence BMD variation, and heritability for this trait has been estimated between 50-80 % (Ralston and de Crombrugghe 2006).…”

Efficacy and tolerability of bazedoxifene in Mexican women with osteoporosis: a subgroup analysis of a randomized phase 3 trial

“…3 As the proportion of the Mexican population aged 50 and over is expected to increase to 37% by 2050 (from 17% in 2009), the prevalence of fractures, associated morbidity, and related healthcare costs are expected to rise steeply. 3,4 For example, the incidence of hip fractures is expected to reach 110,055 to 226,886 by 2050, with associated direct costs of $555 million to $4.088 billion (US$), 4,5 whereas the annual number of hip fractures in Mexico in 2006 was an estimated 22,223, accounting for over $97 million (in 2006 US$) in direct healthcare expenditures. 6 A wide array of prescription medications is available in Mexico for prevention and/or treatment of postmenopausal osteoporosis, including bisphosphonates (risedronate, alendronate, ibandronate, and zoledronic acid), selective estrogen receptor modulators (SERMs; raloxifene and bazedoxifene [BZA]), recombinant parathyroid hormone (teriparatide), denosumab, calcitonin, calcitriol, alfacalcidiol, and strontium ranelate.…”